Cordts SE, et al. - In this single-center cohort study, researchers investigated period prevalence, morbidity, and treatment of hepatitis E virus (HEV) infection in pediatric renal allograft recipients. In this patient population, the reported HEV seroprevalence of 13.3% and an HEV viremia of 4.4% led to the recommendation that HEV infection should be considered in patients with otherwise unexplained elevation of liver enzymes. Effective as well as safe treatment of HEV infection, which does not necessarily respond to reduction of immunosuppressive therapy, could be achieved with ribavirin.